Medical blog

This press release contains forward-looking statements about the business
prospects of BioMarin Pharmaceutical Inc., including, without limitation,
statements about: the expectations related to the retirement of Dr. Kakkis,
the continued clinical development and commercialization of Aldurazyme,
Naglazyme, Kuvan, and its product candidates; and actions by regulatory
authorities. These forward-looking statements are predictions and involve
risks and uncertainties such that actual results may differ materially from
these statements. These risks and uncertainties include, among others:
results and timing of current and planned preclinical studies and clinical
trials; the content and timing of decisions by the U.S. Food and Drug
Administration, the European Commission and other regulatory authorities
concerning each of the described products and product candidates; and those
factors detailed in BioMarin's filings with the Securities and Exchange
Commission, including, without limitation, the factors contained under the
caption "Risk Factors" in BioMarin's 2007 Annual Report on Form 10-K, and the
factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged
not to place undue reliance on forward-looking statements, which speak only as
of the date hereof. BioMarin is under no obligation, and expressly disclaims
any obligation to update or alter any forward-looking statement, whether as a
result of new information, future events or otherwise.